A carregar...
Enzalutamide for treatment of CRPC: Rationale for sequencing and potential clinical biomarker for resistance
The androgen receptor (AR) is central to the initiation and progression of prostate cancer, even after castration. There has been some success in therapies targeting AR signaling which have been shown to extend survival in men with castration-resistant prostate cancer (CRPC). Enzalutamide is a poten...
Na minha lista:
| Publicado no: | Cancer Biol Ther |
|---|---|
| Main Authors: | , , |
| Formato: | Artigo |
| Idioma: | Inglês |
| Publicado em: |
Taylor & Francis
2015
|
| Assuntos: | |
| Acesso em linha: | https://ncbi.nlm.nih.gov/pmc/articles/PMC4622918/ https://ncbi.nlm.nih.gov/pubmed/25569176 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.4161/15384047.2014.987575 |
| Tags: |
Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!
|